Hypotension – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:58 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hypotension – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Angiotensin II in Children and Adolescents With Refractory Hypotension in Distributive Shock https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effects-of-angiotensin-ii-and-sodium-chloride-solution-0-9-in-children-and-adolescents-with-dangerously-low-blood-pressure-during-distributive-shock/ Thu, 07 May 2026 05:47:13 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effects-of-angiotensin-ii-and-sodium-chloride-solution-0-9-in-children-and-adolescents-with-dangerously-low-blood-pressure-during-distributive-shock/ This clinical trial is studying refractory hypotension in distributive shock, which means a very low blood pressure that does not improve easily, even after fluid treatment and medicines that help raise blood pressure. The study is testing angiotensin II, given as an infusion into a vein, compared with placebo, to see whether it can help reduce the amount of other blood pressure medicines needed in children and young people from 0 to 17 years of age.

Participants are placed by chance into one of the study groups and neither the study team nor the family knows which treatment is being given. The study medicine or placebo is added to the usual care already being used for this serious condition. The trial is designed to look at both the benefits and the safety of the treatment during the first hours and days after it is started.

]]> Testing Bisoprolol in Patients with Acute or Recurrent Pericarditis to Reduce Symptoms and Prevent Recurrence https://clinicaltrials.eu/trial/testing-bisoprolol-in-patients-with-acute-or-recurrent-pericarditis-to-reduce-symptoms-and-prevent-recurrence/ Wed, 29 Apr 2026 15:07:45 +0000 https://clinicaltrials.eu/trial/testing-bisoprolol-in-patients-with-acute-or-recurrent-pericarditis-to-reduce-symptoms-and-prevent-recurrence/ This study is looking at pericarditis, which is a condition where the tissue surrounding the heart becomes inflamed. Pericarditis can occur for the first time (acute) or can come back after treatment (recurrent). The medication being tested in this study is bisoprolol, which belongs to a group of medicines called beta-blockers that work by slowing down the heart rate and reducing the workload on the heart.

The purpose of this study is to find out if bisoprolol can help reduce symptoms of pericarditis and prevent the condition from coming back. The study will look at whether the treatment helps symptoms go away within two and four weeks, and whether it lowers the chances of the condition returning within twelve months. Participants will receive bisoprolol at a dose of 1.25 milligrams daily, taken by mouth, for a period of up to 28 days.

During the study, patients will be monitored to see how their symptoms change over time. The study will track whether chest pain and other symptoms continue at different time points, including at one, two, and four weeks. The study will also follow participants for twelve months to see if pericarditis comes back. Additionally, the study will examine the relationship between certain blood test results that show inflammation and heart rate measurements taken at the beginning of the study.

]]> Study of REGN7544 for Treating Adults with Low Blood Pressure Caused by Sepsis https://clinicaltrials.eu/trial/study-of-regn7544-for-treating-adults-with-low-blood-pressure-caused-by-sepsis/ Wed, 29 Apr 2026 15:03:21 +0000 https://clinicaltrials.eu/trial/study-of-regn7544-for-treating-adults-with-low-blood-pressure-caused-by-sepsis/ This clinical trial is focused on studying a condition known as sepsis-induced hypotension, which occurs when a severe infection leads to dangerously low blood pressure. The study will evaluate a treatment using a medication called REGN7544, which is a type of protein designed to help manage this condition. REGN7544 is administered as a solution for injection through an intravenous infusion, meaning it is delivered directly into the bloodstream.

The purpose of the study is to assess how well REGN7544 can reduce the need for medications called vasopressors, which are used to raise blood pressure in patients with sepsis-induced hypotension. Participants in the study will receive either REGN7544 or a placebo, and the effects on their blood pressure and overall health will be monitored. The study will also look at the safety of REGN7544 and how the body processes the medication.

Throughout the study, researchers will collect information on various health indicators, such as blood pressure levels and the amount of vasopressors needed. They will also monitor for any side effects and measure the levels of REGN7544 in the blood. The study aims to provide valuable insights into the potential benefits of REGN7544 for patients with sepsis-induced hypotension.

]]> Study on Early Use of Norepinephrine vs. Standard Fluid Therapy in Emergency Department Patients with Hypotension or Shock https://clinicaltrials.eu/trial/study-on-early-use-of-norepinephrine-vs-standard-fluid-therapy-in-emergency-department-patients-with-hypotension-or-shock/ Wed, 29 Apr 2026 14:26:58 +0000 https://clinicaltrials.eu/trial/study-on-early-use-of-norepinephrine-vs-standard-fluid-therapy-in-emergency-department-patients-with-hypotension-or-shock/ This clinical trial is focused on studying the effects of early treatment for patients experiencing shock or hypotension, which is a condition where blood pressure is lower than normal. The study will compare two different approaches to treatment in the emergency department: using a medication called norepinephrine early on, versus the standard approach of primarily using fluid therapy. Norepinephrine is a type of medication known as a vasopressor, which helps to increase blood pressure by narrowing blood vessels.

The purpose of the study is to see if starting treatment with norepinephrine earlier can help control shock more quickly and reduce the need for patients to be admitted to the intensive care unit (ICU). Participants in the study will be randomly assigned to receive either the early norepinephrine treatment or the standard fluid therapy. The study will monitor how quickly patients achieve stable blood pressure and other outcomes such as the number of days they are alive without needing ICU care within 30 days, the time they spend without shock within 24 hours, and mortality rates both in the hospital and within 30 days.

This trial is designed to provide valuable information on whether early intervention with norepinephrine can improve outcomes for patients with shock or hypotension in emergency settings. The study will be conducted over a period of time, with the aim of gathering enough data to make informed conclusions about the effectiveness of early vasopressor therapy compared to standard care.

]]> Study on Fluid Therapy and Noradrenaline for Low Blood Pressure in Breast Reconstruction Surgery Patients https://clinicaltrials.eu/trial/study-on-fluid-therapy-and-noradrenaline-for-low-blood-pressure-in-breast-reconstruction-surgery-patients/ Wed, 29 Apr 2026 14:26:50 +0000 https://clinicaltrials.eu/trial/study-on-fluid-therapy-and-noradrenaline-for-low-blood-pressure-in-breast-reconstruction-surgery-patients/ This clinical trial is focused on studying arterial hypotension, which is a condition where blood pressure is lower than normal, during a specific type of breast reconstruction surgery known as deep inferior epigastric perforator (DIEP) free flap surgery. The study will explore the effects of a treatment approach called goal-directed fluid therapy, which involves carefully managing the fluids given to patients during surgery to maintain optimal blood pressure and fluid balance.

Two treatments will be used in this study. The first is a solution called Plasma-Lyte® 148 (pH 7.4) solution for infusion, which contains a mix of important salts and minerals like magnesium chloride hexahydrate, potassium chloride, sodium chloride, sodium acetate trihydrate, and sodium gluconate. These substances help maintain the body’s fluid and electrolyte balance. The second treatment is a medication called noradrenaline (norepinephrine) 1 mg/ml concentrate for solution for infusion, which is used to help increase blood pressure by narrowing blood vessels.

The purpose of the study is to investigate how this fluid management strategy affects the amount of fluid given during surgery and its impact on the patient’s recovery. Participants will receive either the treatment or a placebo during their surgery. The study will monitor various factors, such as the total amount of fluid given during surgery, the amount of noradrenaline used, and the patient’s blood pressure and recovery in the intensive care unit. The study aims to provide valuable insights into improving care for patients undergoing DIEP free flap breast reconstruction.

]]>